T1	MajorClaim 167 242	Hormone replacement therapy is often either undesirable or contraindicated.
T2	MajorClaim 243 294	Safe, effective non-hormonal treatments are needed.
T3	Premise 1626 1886	Group CBT significantly reduced HFNS problem rating at 9 weeks after randomisation compared with usual care (mean difference -1·67, 95% CI -2·43 to -0·91; p<0·0001) and improvements were maintained at 26 weeks (mean difference -1·76, -2·54 to -0·99; p<0·0001).
T4	Premise 1887 1929	We recorded no CBT-related adverse events.
T5	Claim 1930 2110	Group CBT seems to be a safe and effective treatment for women who have problematic HFNS after breast cancer treatment with additional benefits to mood, sleep, and quality of life.
R1	Support Arg1:T4 Arg2:T5	
R2	Support Arg1:T3 Arg2:T5	
